RNAZ TransCode Therapeutics, Inc.
$1.69▲ +0.00%
Healthcare
Other
After hours
$1.69▲ +0.00%
Sep 11, 7:30 PM ET
Volume 11.4K
Avg Volume (10D) 119.4K
Key Metrics & Fundamentals
Market Cap
$1.79M
P/E Ratio
–
Div Yield
–%
52W Range
1.63 - 20.99
% vs 50 MA
-64.95%
% vs 200 MA
-76.83%
RSI-14
20.3
MACD Histogram
+0.0600
Beta (1Y vs SPY)
0.85
Free Cash Flow
-$5.40M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$6.69M
COGS
–
Operating Exp
$6.21M
Operating Income
-$6.21M
EBIT
-$6.21M
Pretax Income
-$6.75M
Net Income
-$6.75M
EPS (Diluted)
-7.17
Price & Volume History
Loading chart…
Recent News
TransCode Therapeutics Announces Leadership Transition
PR Newswire · Sep 10, 2026 8:10 PM
Join TransCode Therapeutics' Live Investor Webinar: Advancing a Multi-Platform Oncology Pipeline Targeting Metastatic Cancer
ACCESS Newswire · Sep 3, 2026 1:00 PM
TransCode Therapeutics Announces Publication Demonstrating Survival Benefit of TTX-MC138 in Preclinical Model of Breast Cancer Bone Metastasis
PR Newswire · Aug 31, 2026 12:05 PM
Virax Biolabs and Transcode Therapeutics Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV
ACCESS Newswire · Aug 7, 2026 1:00 PM
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See RNAZ's money flow as a full page
Social Sentiment
Avg -0.30 · 1 posts
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.